Human IgG antibody Laboratories manufactures the sars-cov spike clone 3014 reagents distributed by Genprice. The Sars-Cov Spike Clone 3014 reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact SARS Clone. Other Sars-Cov products are available in stock. Specificity: Sars-Cov Category: Spike Group: Clone 3014
SARS-CoV-2 Spike S2 Peptide |
|||
9123P | ProSci | 0.05 mg | 235.5 EUR |
Description: (CT) SARS-CoV-2 Spike peptide |
|||
Sars-Cov, Spike (Middle) Recom Protein |
|||
abx060656-1mg | Abbexa | 1 mg | 2030.4 EUR |
SARS-CoV-2 Spike Monoclonal Antibody |
|||
A73664-050 | EpiGentek | 50 ul | 341 EUR |
SARS-CoV-2 Spike Monoclonal Antibody |
|||
A73664-100 | EpiGentek | 100 ul | 518.1 EUR |
SARS-CoV-2 Spike RBD Nanobody |
|||
A73680-050 | EpiGentek | 50 ul | Ask for price |
SARS-CoV-2 Spike RBD Nanobody |
|||
A73680-100 | EpiGentek | 100 ul | 882.2 EUR |
SARS-CoV-2 Spike Monoclonal Antibody |
|||
A73664 | EpiGentek |
|
|
SARS-CoV-2 Spike RBD Nanobody |
|||
A73680 | EpiGentek |
|
|
Spike S1 Neutralizing Antibody (SARS-CoV-2) (Clone: 414-2) |
|||
100792 | BPS Bioscience | 100 µg | 460 EUR |
Description: Recombinant human monoclonal (clone 414-2) antibody recognizing the SARS-CoV-2 Spike S1 RBD glycoprotein. This antibody cross-reacts with the Spike protein from the SARS-CoV virus. |
|||
Spike S1 Neutralizing Antibody (SARS-CoV-2) (Clone: 414-1) |
|||
100793 | BPS Bioscience | 100 µg | 485 EUR |
Description: Recombinant human monoclonal (clone 414-1) antibody recognizing the SARS-CoV-2 Spike S1 RBD glycoprotein. This antibody cross-reacts with the Spike protein from the SARS-CoV virus. |
|||
SARS-CoV-2 (COVID-19) Spike Antibody |
|||
3525-002mg | ProSci | 0.02 mg | 206.18 EUR |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
|||
SARS-CoV-2 (COVID-19) Spike Antibody |
|||
3525-01mg | ProSci | 0.1 mg | 523.7 EUR |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
|||
Anti-SARS-CoV-2 Spike S1 Antibody |
|||
A3000-50 | Biovision | 50 µg | 502.8 EUR |
Sars-Cov, Spike (N-Term) Recom Protein |
|||
abx060657-1mg | Abbexa | 1 mg | 2247.6 EUR |
Recombinant Coronavirus Spike Protein (SARS-CoV S2) |
|||
P1519-10 | Biovision | 10µg | 187.2 EUR |
Recombinant Coronavirus Spike Protein (SARS-CoV S2) |
|||
P1519-50 | Biovision | 50µg | 661.2 EUR |
Spike S1, Fc fusion (SARS-CoV-2) |
|||
100688-2 | BPS Bioscience | 50 µg | 505 EUR |
Description: SARS-CoV-2 2019-nCoV Spike protein S1, also known as SARS-CoV s1 and coronavirus spike S1, GenBank Accession No. QHD43416.1, a.a. 16-685, with C-terminal Fc-tag, expressed in a CHO cell expression system. MW= 160 kDa. |